Morphine 6β glucuronide: Fortuitous morphine metabolite or preferred peripheral regulatory opiate?

Medical Science Monitor

Volumn 11, Issue 5, 2005, Pages

  Mantione, Kirk J ^a   Goumon, Yannick ^b   Esch, Tobias ^c   Stefano, George B ^a  

^a STATE UNIVERSITY OF NEW YORK   (United States)

^b INSERM   (France)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Gut; Immune; Morphine; Morphine 6 glucuronide; Mu opiate receptor; Nervous; Nitric oxide; Vascular

Indexed keywords

MORPHINE 6 GLUCURONIDE; MORPHINE DERIVATIVE; OPIATE; OPIATE RECEPTOR; MORPHINE; MORPHINE-6-GLUCURONIDE; MU OPIATE RECEPTOR;

ACTIVE TRANSPORT; ANALGESIA; BLOOD BRAIN BARRIER; BRAIN METABOLISM; CONFERENCE PAPER; DRUG PENETRATION; DRUG POTENCY; DRUG UPTAKE; GENE; MU OPIATE RECEPTOR GENE; NUCLEIC ACID BASE SUBSTITUTION; PARTITION COEFFICIENT; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; ANIMAL; BINDING SITE; BRAIN; EATING; GENETICS; HUMAN; METABOLISM; MOTOR ACTIVITY; PERIPHERAL NERVOUS SYSTEM; PHYSIOLOGY; RESPIRATORY FUNCTION; REVIEW;

ANIMALS; BINDING SITES; BRAIN; EATING; HUMANS; MORPHINE; MORPHINE DERIVATIVES; MOTOR ACTIVITY; PERIPHERAL NERVOUS SYSTEM; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, OPIOID, MU; RESPIRATORY PHYSIOLOGY; SIGNAL TRANSDUCTION;

EID: 20344402554     PISSN: 12341010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (44)

1. Shimomura K, Kamata O. Ueki S et al: Analgesic effect of morphine glucuronides. Tohoku J Exp Med., 1971; 105: 45-52
2. Fiances B, Gout R, Campistron G, Panconi E. Cros J: Morphine-6- glucuronide is more mu-selective and potent in analgesic tests than morphine. Progress in Clinical & Biological Research, 1990; 328: 477-80
3. Mantione R, Zhu W, Rialas C et al: Morphine-6-glucuronide stimulates nitric oxide release in mussel neural tissues: Evidence for a morphine-6-glucnronide opiate receptor subtype. Cellular & Molecular Life Sciences, 2002; 59: 570-74
4. Coffman BL, Rios GR, King CD, Tephly TR: Human UGT2B7 catalyzes morphine glucuronidation. Drug Metab Dispos, 1997; 25: 1-4
5. Yamada H, Ishii R, Ishii Y et al: Formation of highly analgesic morphine-6-glucuronide following physiologic concentration of morphine in human brain. J Toxicol Sci, 2003; 28: 395-401
6. Nagano E, Yamada H, Oguri K: Characteristic glucuronidation pattern of physiologic concentration of morphine in rat brain. Life Sci, 2000; 67: 2453-454
7. Christrup LL: Morphine metabolites. Acta Anaesthesiol Scand, 1997; 41: 116-22
8. Okuva T, Saito M, Nakanishi M et al.: Different distribution of morphine and morphine-6 beta-glncuronide after intracerebroventricular injection in rats. Br J Pharmacol, 2003; 140: 211-17
9. Makman MH, Dvorkin B, Stefano GB: Murine macrophage cell lines contain m3-opiate receptors. Eur J Pharmacol, 1995; 273: R5-R6
10. Wu D, Kang YS, Bickel U, Pardridge WM: Blood-brain barrier permeability to morphine-6-glucuronide is markedly reduced compared with morphine. Drug Metabolism & Disposition, 1997; 25: 768-71
11. Huwyler J, Drewe J, Klusemann C, Flicker G: Evidence for P-glycoprotein-modulated penetration of morphine-6-glucuronide into brain capillary endothelium. Br J Pharmacol, 1996; 118: 1879-85
12. Bourasset F, Cisternino S, Temsamani J, Scherrman JM: Evidence for an active transport of morphine-6-beta-d-glucuronide but not P-glycoprotein- mediated at the blood-brain barrier. J Neurochem. 2003; 86: 1564-67
13. Skarke C, Langer M, Jarrar M et al: Probenecid interacts with the pharmacokinetics of morphitie-6-glucuronide in humans. Anesthesiology, 2004; 101: 1394-99
14. Tunblad K. Hammarlund-Udenaes M, Jonsson EN: Influence of probenecid on the deliveiy of morphine-6-glucuronide to the brain. Eur J Pharm Sci, 2005; 24: 49-57
15. Rossi GC, Pan YX, Brown GP, Pasternak GW: Antisense mapping of the MOR-1 opioid receptor: evidence for alternative splicing and a novel morphine-6 beta-glucuionide receptor. FEBS Lett, 1995; 369: 192-96
16. Rossi GC, Standifer KM, Pasternak GW: Differential blockade of morphine and morphine-6 beta-glucuronide analgesia by anti.sense oligodeoxynucleotides directed against MOR-1 and G-protein alpha subtinils in rats. Neurosci Lett, 1995; 198: 99-102
17. Grung M, Skurtveit S, Aasnmndstad TA et al: Morphine-6-glucuronide- induced locomotor stimulation in mice: role of opioid receptors. Pharmacol Toxicol. 1998; 82: 3-10
18. Romberg R, Sarton E, Teppema L et al: Comparison of morphine-6- glucuronide and morphine on respiratoiy depressant and antinociceptive responses in wild type and mu-opioid receptor deficient mice. Br J Anaesth. 2003; 91: 862-70
19. Greenwood-Van Meerveld B, Gardner CJ, Little PJ et al: Preclinical studies of opioids and opioid antagonists on gastrointestinal function. Neurogastroenterol Motil, 2004; 16(Suppl.2): 46-53
20. Broivn GP, Vang K, Ouerfelli O et al: 3H-morphine-6beta-glucuronide binding in brain membranes and an MOR-1-transfected cell line. J Pharmacol Exp Thev, 1997; 282: 1291-97
21. Schuhet AGP, King MA, Zhang J et al: Retention of heroin and inorphine-6b-ghicnronrde analgesia in a new line of mice lacking exon 1 of MOR-1. Nature Neuroscience. 1999; 2: 151-56
22. Grung M, Skurtveit S, Ripel A, Morland J: Lack of crosstolerance between morphine and morplmie-6-ghicmonide as revealed by locomotor activity, Pharmacology. Biochemistry & Behavior, 2000; 66: 205-10
23. Silva RM, Rossi GC, Mathis JP et al: Morphine and morphine-6beta- glucuronide-induced feeding are differentially reduced by G-protein alpha-subunit antisense probes in rats. Brain Res. 2000; 876: 62-75
24. Romberg R, Olofsen E, Sarton E et al: Pharmacodynamic effect of morphine-6-glucuronide versus morphine on hypoxic and hypercapnic breathing in health volunteers. Anesthesiology, 2003; 99: 788-98
25. Stefano GB, Hartman A, Bilfinger TV et al: Presence of the mu3 opiate receptor in endothelial cells: Coupling to nitric oxide production and vasodilation. J Biol Chem, 1995; 270: 30290-93
26. Stefano GB, Scharver B, Smith EM et al: Opioid and opiate immunoregulatory processes. Crit Rev in Immunol. 1996; 16: 109-44
27. Stefano GB: Autoimmunovascular regulation: morphine and anandamide stimulated nitric oxide release. Journal of Neuroimmunology. 1998; 83: 70-76
28. Stefano GB, Goumon Y, Bilfinger TV et al: Basal nitric oxide limits immune, nervous and cardiovascular excitation: Human endothelia express a mu opiate receptor. Progress in Neurobiology, 2000; 60: 531-44
29. Stefano GB, Goumon Y, Casares F et al: Endogenous morphine. Trends in Neurosciences, 2000; 9: 436-42
30. Cadet P, Mantione KJ, Stefano GB: Molecular identification and functional expression of mu3, a novel alternatively spliced variant of the human mu opiate receptor gene. Journal of Immunology, 2003; 170: 5118-23
31. Stefano GB, Salzet M, Magazine HI. Bilfinger TV: Antagonist of LPS and IFN-g induction of iNOS in human saphenous vein endothelium by morphine and anandamide by nitric oxide inhibition of adenylate cyclase. J Cardiovasc Pharmacol, 1998; 31: 813-20
32. Lysle DT, Carrigan KA: Morphine-6beta-ghicuiOnide modulates the expression of inducible nitric oxide synthase. Inflammation, 2001; 25: 267-75
33. Pasternak GW: Insights into mu opioid pharmacology the role of mu opioicl receptor subtypes. Life Sciences, 2001; 68: 2213-19
34. Bond C, LaForge KS, Tian M et al: Single-nncleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci USA, 1998; 95: 9608-13
35. Lotsch J, Skarke C, Grosch S et al: The polymorphism A118G of the human mu-opioid receptor gene decreases the pupil constrictory effect of morphine-6-glucuronide but not that of morphine, Pharmacogenetics, 2002; 12: 3-9
36. Lotsch J, Zimmermann M, Darimont J et al: Does the A118G polymorphism at the mu-opioid receptor gene protect against morphine-6-glucuronide toxicity? Anesthesiology, 2002; 97: 814-19
37. Hollt V: A polymorphism (A118G) in the mm-opioid receptor gene affects the response to morphine-6-glucuronide in humans. Pharmacogenetics, 2002; 12: 1-2
38. Beyer A, Koch T, Schroder H et al: Effect of the A118G polymorphism on binding affinity, potency and agonist-mediated endocytosis, desensilization and resensitization of the human mu-opioid receptor. J Neurochem, 2004; 89: 553-60
39. Zhu W, Bilfinger TV, Baggerman G et al: Presence of endogenous morphine and morphine 6 glucuronide in human heart tissue. International Journal of Molecular Medicine. 2001; 7: 419-22
40. Zhu W, Baggerman G, Goumori V et al: Presence of morphine and morphine-glucuronide in the marine mollusk Mytillus edulis ganglia determined by GC/MS and Q-TOF-MS. Starvation increases opiate alkaloid levels. Brain Res Mol Brain Res, 2001; 88: 155-60
41. Cadet P, Stefano GB: Mytilus edulis pedal ganglia express μ opiate receptor transcripts exhibiting high sequence identity with human neuronal μl. Mol Brain Res, 1999; 74: 242-46
42. Brix-Christensen V, Tonnesen E, Sanchez RG et al: Endogenous morphine levels increase following cardiac surgery as part of the antiinflammatory response? Int J Cardiol, 1997; 62: 191-97
43. Gonmon Y, Bouret S, Casares F et al: Lipopolysaccharide increases endogenous morphine levels in rat brain. Neuroscience Letters, 2000; 293: 135-38
44. Lee CS, Spector S: Changes of endogenous morphine and codeine contents in the fasting eat. J Pharmacol Exp Ther, 1991; 257: 647-50